United Therapeutics (NASDAQ:UTHR – Get Rating) had its target price hoisted by Argus from $250.00 to $300.00 in a research note published on Wednesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company's stock.

A number of other analysts also recently weighed in on the stock. UBS Group started coverage on shares of United Therapeutics in a research report on Tuesday, December 6th. They set a buy rating and a $320.00 price target on the stock. The Goldman Sachs Group initiated coverage on United Therapeutics in a research note on Monday, December 5th. They issued a sell rating and a $230.00 price target on the stock. Morgan Stanley upped their price objective on United Therapeutics from $322.00 to $330.00 and gave the stock an overweight rating in a research report on Tuesday, December 6th. Wedbush lifted their target price on United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. Finally, JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $240.00 to $265.00 and gave the stock an overweight rating in a report on Thursday, November 3rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $283.64.

United Therapeutics Trading Down 0.2 %

Shares of UTHR stock opened at $261.04 on Wednesday. The stock has a market cap of $11.90 billion, a P/E ratio of 17.76, a price-to-earnings-growth ratio of 1.56 and a beta of 0.62. United Therapeutics has a 1 year low of $158.38 and a 1 year high of $283.09. The company has a current ratio of 9.68, a quick ratio of 9.39 and a debt-to-equity ratio of 0.18. The stock has a 50 day simple moving average of $271.03 and a 200 day simple moving average of $240.39.

Insider Buying and Selling

In related news, Director Nilda Mesa sold 290 shares of the business's stock in a transaction on Monday, November 7th. The shares were sold at an average price of $268.57, for a total value of $77,885.30. Following the sale, the director now owns 6,180 shares of the company's stock, valued at $1,659,762.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Nilda Mesa sold 290 shares of the business's stock in a transaction on Monday, November 7th. The shares were sold at an average price of $268.57, for a total value of $77,885.30. Following the sale, the director now owns 6,180 shares of the company's stock, valued at $1,659,762.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Louis W. Sullivan sold 700 shares of the business's stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $230.28, for a total transaction of $161,196.00. Following the completion of the sale, the director now directly owns 12,180 shares in the company, valued at approximately $2,804,810.40. The disclosure for this sale can be found here. Insiders have sold a total of 183,390 shares of company stock valued at $48,335,135 over the last 90 days. 12.40% of the stock is owned by insiders.

Institutional Trading of United Therapeutics

Institutional investors have recently bought and sold shares of the company. Calamos Advisors LLC bought a new stake in United Therapeutics during the second quarter valued at $525,000. UMB Bank n.a. boosted its position in United Therapeutics by 91.8% during the second quarter. UMB Bank n.a. now owns 1,306 shares of the biotechnology company's stock valued at $308,000 after acquiring an additional 625 shares during the last quarter. Hallmark Capital Management Inc. bought a new stake in United Therapeutics during the second quarter valued at $33,000. Roman Butler Fullerton & Co. bought a new stake in United Therapeutics during the second quarter valued at $1,573,000. Finally, TriaGen Wealth Management LLC bought a new stake in United Therapeutics during the second quarter valued at $320,000. Institutional investors own 95.63% of the company's stock.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Stories

• Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
• MarketBeat: Week in Review 01/09-01/13
• JPMorgan Chase Falls As Banks Brace For Recession
• Why is the Bed Bath & Beyond Stock Price up 261%?
• Roku Stock Price is Trending, Here's Why
• Carvana Stock Rally, Here's What You Need to Know

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.